Johnson & Johnson Stock Moves Higher After Delivering Robust Q3 Growth

Oct 14 - Johnson & Johnson JNJ shares edged higher on early Monday after the healthcare giant posted better-than-expected third-quarter earnings and raised its full-year guidance.

The company reported adjusted earnings per share of $2.80, topping analysts' estimates by $0.04, while revenue rose 6.7% year over year to $24 billion, about $240 million above forecasts. The performance reflected continued strength in J&J's pharmaceutical and medical technology segments.

For fiscal 2025, Johnson & Johnson now expects operational sales of about $93.0 billion to $93.4 billion, reported sales of about $93.5 billion to $93.9 billion, and reaffirmed adjusted EPS guidance of $10.80 to $10.90.

The company also reaffirmed its adjusted operational EPS outlook at $10.63 to $10.73, and its adjusted EPS between $10.80 and $10.90, implying annual growth of roughly 8% to 9%.

Consensus estimates for the year sit near $93.46 billion in sales and $10.85 in adjusted EPS, suggesting Johnson & Johnson remains on track to meet, or slightly exceed, Wall Street expectations.